PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.42
Negative P/E while Biotechnology median is -5.90. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
3.78
P/B 1.25-1.5x Biotechnology median of 2.89. Guy Spier would scrutinize if premium reflects better asset utilization.
-6.71
Negative FCF while Biotechnology median P/FCF is -24.69. Seth Klarman would investigate cash flow improvement potential.
-6.71
Negative operating cash flow while Biotechnology median P/OCF is -24.69. Seth Klarman would investigate operational improvement potential.
3.78
Fair value ratio 1.25-1.5x Biotechnology median of 2.94. Guy Spier would scrutinize if premium reflects durable advantages.
-17.57%
Negative earnings while Biotechnology median yield is -2.72%. Seth Klarman would investigate path to profitability.
-14.90%
Negative FCF while Biotechnology median yield is -2.17%. Seth Klarman would investigate cash flow improvement potential.